赛胃安胶囊联合雷贝拉唑治疗十二指肠溃疡的临床研究

Clinical study on Saiweian Capsules combined with rabeprazole in treatment of duodenal ulcer

目的探讨采用赛胃安胶囊联合雷贝拉唑治疗十二指肠溃疡患者的临床疗效。方法选取2015年6月—2017年6月昌江黎族自治县人民医院收治的十二指肠溃疡患者83例,根据治疗方案的不同分成对照组(41例)和治疗组(42例)。对照组患者口服雷贝拉唑钠肠溶胶囊,20 mg/次,1次/d;治疗组患者在对照组基础上口服赛胃安胶囊,3粒/次,3次/d。两组患者均连续治疗6周。观察两组患者临床疗效,同时比较治疗前后两组患者幽门螺杆菌根除率、溃疡面积和消化道症状积分、肿瘤坏死因子-α(TNF-α)、核因子-κB(NF-κB)和高迁移率族蛋白B1(HMGB1)及不良反应情况。结果治疗后,对照组临床有效率和幽门螺杆菌根除率分别为78.05%和70.73%,均分别明显低于治疗组的95.24%和90.48%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者的溃疡面积和消化道症状积分均显著减小(P<0.05),同时治疗组患者在溃疡面积和消化道症状积分改善方面均明显优于对照组患者(P<0.05)。治疗后,两组患者的血清TNF-α、NF-κB和HMGB1水平均显著降低(P<0.05),且治疗组患者血清TNF-α、NF-κB和HMGB1水平明显低于对照组患者(P<0.05)。治疗期间,对照组不良反应发生率为21.95%,明显高于治疗组的4.76%,两组比较差异具有统计学意义(P<0.05)。结论赛胃安胶囊联合雷贝拉唑治疗十二指肠溃疡患者可显著提升患者的临床有效率和幽门螺杆菌根除率,安全性较高,具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Saiweian Capsules combined with rabeprazole in treatment of duodenal ulcer. Methods Patients（83 cases） with duodenal ulcer in Changjiang Li Nationality Autonomous County People＇s Hospital from June 2015 to June 2017 were divided into control（41 cases） and treatment（42 cases） groups based on different treatments. Patients in the control group were po administered with Rabeprazole Sodium Enteric-coated Capsules, 20 mg/time, once daily. Patients in the treatment group were po administered with Saiweian Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the Helicobacter pylori eradication rate, the ulceration area and digestive tract symptoms scores, the serum TNF-α, NF-κB, and HMGB1 levels, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and Helicobacter pylori eradication rate in the control group were 78.05% and 70.73%, which were significantly lower than 95.24% and 90.48% in the treatment group, respectively, and there were differences between two groups（P〈 0.05）. After treatment, the ulceration area and digestive tract symptoms scores in two groups were significantly decreased（P〈 0.05）, and these scores in the treatment group after treatment were significantly better than those in the control group（P〈 0.05）. After treatment, the TNF-α, NF-κB, and HMGB1 levels in two groups were significantly decreased（P〈 0.05）, and these serum indexes in the treatment group after treatment were significantly lower than those in the control group（P〈 0.05）. During the treatment, the adverse reactions rate in the control group was 21.95%, which was significantly higher than 4.76% in the treatment group, with significant difference between two groups（P〈 0.05）. Conclusion Saiweian Capsules combined with rabeprazole in treatment of duodenal ulcer can significantly improve the clinical efficacy and eradication rate of Helicobacter pylori with high safety, which has a certain clinical application value.